Oscient reiterated at strong buy by Merrill

Merrill Lynch analyst Adam Cutler reiterated Oscient Pharmaceuticals Corp. at a strong buy after Factive five-day treatment for community acquired pneumonia received an approvable letter from the Food and Drug Administration. Oscient must provide the FDA with some additional information and should do so in the next few weeks. Shares of the Waltham, Mass., biopharmaceutical company were up 13 cents, or 13.13%, at $1.12. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.